IN BRIEF: Motif Bio Making Progress On UK Drug Development Firm Buy

Motif Bio PLC - AIM cash shell - Continues to progress a reverse takeover under the head of terms ...

Alliance News 27 January, 2021 | 2:37PM
Email Form

Motif Bio PLC - AIM cash shell - Continues to progress a reverse takeover under the head of terms agreement signed with a UK-based antibody drug conjugate discovery and development firm. Subject to execution of a sale and purchase agreement, the deal would see Motif acquire the undisclosed target's entire share capital. Motif is to remain suspended from trading while the proposed transaction is being negotiated and advanced, with further updates "as appropriate".

The acquisition, classified as a reverse takeover, is subject to completion of the share purchase agreement, shareholder approval, and the raising of enough equity to accelerate the target's development programmes. A rule 9 waiver from the UK takeover panel over the proposed issue of new shares to the target and admission of the enlarged group to AIM trading is also needed. A share consolidation and name change are intended alongside fundraising.

Motif President & Chief Business Officer Jonathan Gold: "The Motif directors are encouraged by the way the proposed transaction is progressing and I look forward to providing our shareholders with further updates and additional information regarding the target in due course."

Current stock price: Suspended, last trading July 2020

By Anna Farley; annafarley@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Motif Bio PLC 0.50 GBX 26.58 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies